# Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis

> **NCT04947826** · PHASE2 · UNKNOWN · sponsor: **Shanghai Zhongshan Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Hepatocellular Carcinoma With Major Portal Vein Thrombosis

## Interventions

- **PROCEDURE:** HAIC (Hepatic arterial infusion chemotherapy)
- **DRUG:** HLX10 (PD-1 antibody)
- **DRUG:** HLX04 (VEGF antibody)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04947826
- **Lead sponsor:** Shanghai Zhongshan Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08
- **Primary completion:** 2024-07
- **Final completion:** 2024-07
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2021-07-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04947826

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04947826, "Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04947826. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*